- Co-MOF-Derived Hierarchical Mesoporous Yolk-shell-structured Nanoreactor for the Catalytic Reduction of Nitroarenes with Hydrazine Hydrate
-
Porous nanoreactors demonstrate immense potential for applications in heterogeneous catalysis due to their excellent mass-transfer performance and stability. The design of a simple, universal strategy for fabricating nanoreactor catalysts is of significance for organic transformation. In this study, a nanoreactor with a hierarchical mesoporous yolk-shell structure was successfully prepared by the high-temperature carbonization of a ZIF-67@polymer composite. The core of the resultant Co@ZDC@mC material comprised Co NPs anchored in the ZIF-67-derived carbon framework, while the shell comprised resin-polymer-derived mesoporous carbon. The as-obtained Co@ZDC@mC-700 catalyst enriched reactants, efficiently catalyzed the reaction in the core, and permitted the desorption of the product from the nanoreactor. In the catalytic reduction of nitrobenzene with N2H4?H2O, Co@ZDC@mC-700 exhibited superior catalytic efficiency (TOF=1136.3 h?1). In addition, Co@ZDC@mC-700 exhibited excellent performance for the catalytic reduction of various functionalized nitroarenes, as well as good reusability and recyclability. Hence, a simple, useful approach for fabricating a metal-organic-framework-derived non-noble metal-based yolk-shell nanoreactor for effective catalytic transformation is proposed.
- Yuan, Man,Zhang, Hongbo,Yang, Chen,Wang, Fanhao,Dong, Zhengping
-
-
Read Online
- Mechanochemical Transformation of CF3 Group: Synthesis of Amides and Schiff Bases
-
We communicate two mild, solvent-free mechanochemical coupling transformations of CF3 group with nitro compounds into amides or Schiff bases employing Ytterbia as a catalyst. This process proceeds via C?F bond activation, accompanied with utilisation of Si-based reductants/oxygen scavengers – reductants of the nitro group. The scope and limitations of the disclosed methodologies are thoroughly studied. To the best of our knowledge, this work is the first example of mechanical energy promoted transformation of the inert CF3 group into other functionalities. (Figure presented.).
- Mkrtchyan, Satenik,Jakubczyk, Micha?,Lanka, Suneel,Yar, Muhammad,Ayub, Khurshid,Shkoor, Mohanad,Pittelkow, Michael,Iaroshenko, Viktor O.
-
supporting information
p. 5448 - 5460
(2021/10/19)
-
- Anion ligand promoted selective C-F bond reductive elimination enables C(sp2)-H fluorination
-
A detailed mechanism study on the anion ligand promoted selective C-H bond fluorination is reported. The role of the anion ligand has been clarified by experimental evidence and DFT calculations. Moreover, the nitrate promoted C-F bond reductive elimination enabled a selective C-H bond fluorination of various symmetric and asymmetric azobenzenes to access diverse o-fluoroanilines.
- Mao, Yang-Jie,Luo, Gen,Hao, Hong-Yan,Xu, Zhen-Yuan,Lou, Shao-Jie,Xu, Dan-Qian
-
p. 14458 - 14461
(2019/12/09)
-
- Aminal-based Hypercrosslinked Polymer Modified with Small Palladium Nanoparticles for Efficiently Catalytic Reduction of Nitroarenes
-
Fabrication of heterogeneous catalysts with excellent activity, selectivity and stability is significant for various catalytic applications. Here, we prepared a hypercrosslinked polymer (HCP) via a facile and cost-effective strategy using ferrocenecarboxaldehyde and melamine as building blocks. Then, the HCP was modified with highly dispersed ultrafine Pd nanoparticles (Pd/HCP). The obtained Pd/HCP shows excellent catalytic activity in the catalytic reduction of nitroarenes under mild reaction conditions. It′s worth mentioning that the N atoms in the HCP can efficiently coordinate Pd ions to form small Pd nanoparticles (NPs) and subsequently prevent the aggregation and leaching of Pd NPs during the reaction, so the Pd/HCP catalyst is highly stable and can be reused at least eight cycles without loss of catalytic activity. Therefore, this work may provide possibilities for using HCPs as ideal supporting materials for fabricating highly stable and efficient heterogeneous catalysts.
- Xu, Dan,Wang, Fushan,Yu, Guiqin,Zhao, Hong,Yang, Jing,Yuan, Man,Zhang, Xiaoyun,Dong, Zhengping
-
p. 4569 - 4577
(2018/09/11)
-
- NOVEL COMPOUNDS AS REARRANGED DURING TRANSFECTION (RET) INHIBITORS
-
This invention relates to novel compounds which are inhibitors of the Rearranged during Transfection (RET) kinase, to pharmaceutical compositions containing them, to processes for their preparation, and to their use in therapy, alone or in combination, for the normalization of gastrointestinal sensitivity, motility and/or secretion and/or abdominal disorders or diseases and/or treatment related to diseases related to RET dysfunction or where modulation of RET activity may have therapeutic benefit including but not limited to all classifications of irritable bowel syndrome (IBS) including diarrhea-predominant, constipation-predominant or alternating stool pattern, functional bloating, functional constipation, functional diarrhea, unspecified functional bowel disorder, functional abdominal pain syndrome, chronic idiopathic constipation, functional esophageal disorders, functional gastroduodenal disorders, functional anorectal pain, inflammatory bowel disease, proliferative diseases such as non-small cell lung cancer, hepatocellular carcinoma, colorectal cancer, medullary thyroid cancer, follicular thyroid cancer, anaplastic thyroid cancer, papillary thyroid cancer, brain tumors, peritoneal cavity cancer, solid tumors, other lung cancer, head and neck cancer, gliomas, neuroblastomas, Von Hippel-Lindau Syndrome and kidney tumors, breast cancer, fallopian tube cancer, ovarian cancer, transitional cell cancer, prostate cancer, cancer of the esophagus and gastroesophageal junction, biliary cancer, adenocarcinoma, and any malignancy with increased RET kinase activity.
- -
-
Paragraph 0485; 0486
(2014/09/30)
-
- PYRIDINE DERIVATIVES AS REARRANGED DURING TRANSFECTION (RET) KINASE INHIBITORS
-
This invention relates to novel compounds which are inhibitors of the Rearranged during Transfection (RET) kinase, to pharmaceutical compositions containing them, to processes for their preparation, and to their use in therapy, alone or in combination, for the normalization of gastrointestinal sensitivity, motility and/or secretion and/or abdominal disorders or diseases and/or treatment related to diseases related to RET dysfunction or where modulation of RET activity may have therapeutic benefit including but not limited to all classifications of irritable bowel syndrome (IBS) including diarrhea-predominant, constipation-predominant or alternating stool pattern, functional bloating, functional constipation, functional diarrhea, unspecified functional bowel disorder, functional abdominal pain syndrome, chronic idiopathic constipation, functional esophageal disorders, functional gastroduodenal disorders, functional anorectal pain, inflammatory bowel disease, proliferative diseases such as non-small cell lung cancer, hepatocellular carcinoma, colorectal cancer, medullary thyroid cancer, follicular thyroid cancer, anaplastic thyroid cancer, papillary thyroid cancer, brain tumors, peritoneal cavity cancer, solid tumors, other lung cancer, head and neck cancer, gliomas, neuroblastomas, Von Hippel-Lindau Syndrome and kidney tumors, breast cancer, fallopian tube cancer, ovarian cancer, transitional cell cancer, prostate cancer, cancer of the esophagus and gastroesophageal junction, biliary cancer, adenocarcinoma, and any malignancy with increased RET kinase activity.
- -
-
Page/Page column 109
(2014/09/29)
-
- SUBSTITUTED QUINAZOLINE DERIVATIVES AND THEIR USE AS INHIBITORS
-
The use of a compound of formula (I) 1 or a salt, ester or amide thereof; where X is O, or S, S(O) or S(O)2, or NR6 where R6 is hydrogen or C1-6 alkyl,; R5 is an optionally substituted 5-membered heteroaromatic ring, R1, R2 ,R3, R4 are independently selected from various specified moieties, in the preparation of a medicament for use in the inhibition of aurora 2 kinase. Certain compounds are novel and these, together with pharmaceutical compositions containing them are also described and claimed
- -
-
-
